KA/EN
Register
Medicines reference
Search
Search
Active substance

Triamcinolone

Favourites

Intermediate-acting glucocorticoid. Registered in Georgia: 2 veterinary products. Forms: ear drops.

Dose and use

Doses

We have no dose with a cited source for this substance yet.

Before use

Safety information

Known Contraindications

  • Critical
    Do not use in hypersensitivity to the substance, the other components or corticosteroids.
    Sources: Czech SPC
Latin name
Triamcinolone
Georgian name
ტრიამცინოლონი
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
2 of 2 forms
Products
Otibiovin, OTOPET THERAPY
Human medicines in Georgia
Ftorocort, Kenalog, Polcortolon, Proctosteroid, Triam-Denk
Human medicines with this substance in the Georgian register of medicines (Ministry of Health), checked on 18 Oct 2026. They are human medicines, not veterinary products; strengths and forms differ.
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026
All forms and registration2

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Otibiovin, Ear drops

triamcinolone acetonide 0.5 mg + salicylic acid 5 mg + gentamicin sulfate 2 mg + carbethopendecinium bromide 0.125 mg per ml, ear drops
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Label-concordant treatment of severe canine external otitis caused by susceptible organisms, with intact tympanum, diagnostic support and primary-cause management
6.0/10
Situational / acceptable
vetman assessment

Otibiovin

triamcinolone acetonide 0.5 mg + salicylic acid 5 mg + gentamicin sulfate 2 mg + carbethopendecinium bromide 0.125 mg per ml, ear drops
Assessed clinical scopeDog · Label-concordant treatment of severe canine external otitis caused by susceptible organisms, with intact tympanum, diagnostic support and primary-cause management · Into the ear
Care settingVeterinary otoscopy and cytology before cleaning, intact-tympanum confirmation, susceptibility-led selection for severe/recurrent infection, instructed high-frequency home treatment and planned clinical/cytological recheck
vetman score 6.0/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, veterinary · Verified on 22 Oct 2026

A transparent authorised option for a narrow, diagnosed susceptible canine otitis role, but not an empirical all-purpose ear drop: intact tympanum, susceptibility, primary-cause treatment and demanding frequent dosing determine value.

Regulatory and scientific credibility7.5/10

The exact dog/cat formulation, dose, strict indication restriction and 12-day open life are transparent, with current Georgian and Czech/EU authorisation. The regulator document is old and no independent exact-product trial or broad pharmacovigilance record was identified.

Clinical efficacy6.0/10

Gentamicin, anti-inflammatory triamcinolone, salicylic acid and cationic antiseptic are mechanistically coherent for selected susceptible otitis. Historical isolates showed 90% overall and 85% Pseudomonas gentamicin susceptibility, not universal coverage; no exact-product trial and no conventional dedicated antifungal limit confidence.

Safety and tolerability5.5/10

An intact tympanum materially reduces risk, and the exact label reports no known adverse effects, but topical gentamicin remains potentially ototoxic. Steroid masking/immunosuppression, irritation from salicylic acid/ethanol/antiseptic, low systemic antibiotic exposure and a painful diseased canal require active monitoring.

Clinical practicality4.5/10

Four to five drops three to four times daily, then two to three times daily, plus cleaning/massage for up to 12 days is measurable but demanding for home adherence. Pain, canal stenosis, resistant infection and frequent handling may make treatment unreliable without demonstration and early recheck.

Full-course cost-effectiveness-

Current Georgian full-course price and presentation-specific wastage cost were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Hard stop: confirm an intact tympanic membrane before use. Do not use with rupture or when middle-ear exposure cannot be responsibly excluded. Gentamicin may be ototoxic, especially beyond an abnormal tympanum.
  • Obtain cytology before cleaning and diagnose the primary cause. The exact label restricts use to serious infection supported by pathogen identification, susceptibility to the active and resistance to common antibiotics; do not use as an empirical all-purpose ear drop.
  • Dose is 4–5 drops into the affected external canal 3–4 times daily initially, then 2–3 times daily after three days; massage gently. Usual duration is 5–7 days and the absolute label maximum is 12 days.
  • Recheck clinically and cytologically. Stop and urgently assess new hearing loss, head tilt, nystagmus, ataxia, vertigo, facial-nerve change, marked pain or worsening discharge; investigate otitis media rather than continuing blindly.
  • Gentamicin susceptibility is not universal and historical Pseudomonas coverage was about 85%. Culture/susceptibility is especially important for rods, severe/recurrent disease, prior antimicrobial exposure or poor response; minimise resistance selection.
  • No conventional dedicated antifungal or acaricide is present. Treat confirmed yeast/fungal disease and Otodectes with an appropriate effective plan; in-vitro gentamicin inhibition of Malassezia is not clinical antifungal equivalence.
  • Triamcinolone can reduce inflammation and pain but can mask progression, delay healing, promote secondary infection and cause local/systemic glucocorticoid effects. Do not extend beyond 12 days or repeat courses without re-diagnosis.
  • Salicylic acid, ethanol and carbethopendecinium can irritate an eroded inflamed canal. Do not add another cleaner or drop unless compatibility, spacing and tympanic safety are established; avoid traumatic cleaning.
  • Low systemic antibiotic concentrations can occur after routine topical otic treatment. Consider total aminoglycoside exposure, renal/neuromuscular vulnerability and concurrent ototoxic drugs when the canal is severely inflamed or treatment is repeated.
  • Shake to redisperse permitted slight sediment, avoid dropper contact/cross-ear contamination, label first opening, store below 25 °C protected from light and discard after 12 days. Wear gloves, wash hands and avoid eye/skin/mucosal contact or ingestion.
Assessment sources
  1. Otibiovin Czech SPC2011
  2. Otibiovin exact2026
  3. MSD otitis externa2026
  4. Topical otic review2016
  5. Otitis susceptibility2006
  6. Otomax VMD control2026
  7. Otomax FDA control2026
  8. Otic systemic exposure2012
  9. Pseudomonas review2007
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Label-concordant treatment of severe feline external otitis caused by susceptible organisms, with intact tympanum, diagnostic support and primary-cause management
5.7/10
Weak evidence support
vetman assessment

Otibiovin

triamcinolone acetonide 0.5 mg + salicylic acid 5 mg + gentamicin sulfate 2 mg + carbethopendecinium bromide 0.125 mg per ml, ear drops
Assessed clinical scopeCat · Label-concordant treatment of severe feline external otitis caused by susceptible organisms, with intact tympanum, diagnostic support and primary-cause management · Into the ear
Care settingVeterinary otoscopy and cytology before cleaning, intact-tympanum confirmation, susceptibility-led selection for severe/recurrent infection, instructed high-frequency home treatment and planned clinical/cytological recheck
vetman score 5.7/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · Verified on 22 Oct 2026

Authorised for cats, but direct feline outcomes are absent and the high-frequency gentamicin/steroid regimen has important diagnostic, ototoxicity, spectrum and handling constraints; reserve for well-supported susceptible cases.

Regulatory and scientific credibility7.5/10

The exact dog/cat formulation, dose, strict indication restriction and 12-day open life are transparent, with current Georgian and Czech/EU authorisation. The regulator document is old and no independent exact-product trial or broad pharmacovigilance record was identified.

Clinical efficacy5.0/10

The exact label includes cats and mixed-species susceptibility data support possible activity, but no independent feline Otibiovin outcome study was identified. Feline causes differ, gentamicin coverage is incomplete and the formula lacks a conventional dedicated antifungal.

Safety and tolerability5.5/10

An intact tympanum materially reduces risk, and the exact label reports no known adverse effects, but topical gentamicin remains potentially ototoxic. Steroid masking/immunosuppression, irritation from salicylic acid/ethanol/antiseptic, low systemic antibiotic exposure and a painful diseased canal require active monitoring.

Clinical practicality4.0/10

The same high-frequency schedule is particularly burdensome in many cats and can increase restraint stress, missed doses and dropper contamination. Feline-friendly handling, pain control, demonstration and an early recheck are central to feasibility.

Full-course cost-effectiveness-

Current Georgian full-course price and presentation-specific wastage cost were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Hard stop: confirm an intact tympanic membrane before use. Do not use with rupture or when middle-ear exposure cannot be responsibly excluded. Gentamicin may be ototoxic, especially beyond an abnormal tympanum.
  • Obtain cytology before cleaning and diagnose the primary cause. The exact label restricts use to serious infection supported by pathogen identification, susceptibility to the active and resistance to common antibiotics; do not use as an empirical all-purpose ear drop.
  • Dose is 4–5 drops into the affected external canal 3–4 times daily initially, then 2–3 times daily after three days; massage gently. Usual duration is 5–7 days and the absolute label maximum is 12 days.
  • Recheck clinically and cytologically. Stop and urgently assess new hearing loss, head tilt, nystagmus, ataxia, vertigo, facial-nerve change, marked pain or worsening discharge; investigate otitis media rather than continuing blindly.
  • Gentamicin susceptibility is not universal and historical Pseudomonas coverage was about 85%. Culture/susceptibility is especially important for rods, severe/recurrent disease, prior antimicrobial exposure or poor response; minimise resistance selection.
  • No conventional dedicated antifungal or acaricide is present. Treat confirmed yeast/fungal disease and Otodectes with an appropriate effective plan; in-vitro gentamicin inhibition of Malassezia is not clinical antifungal equivalence.
  • Triamcinolone can reduce inflammation and pain but can mask progression, delay healing, promote secondary infection and cause local/systemic glucocorticoid effects. Do not extend beyond 12 days or repeat courses without re-diagnosis.
  • Salicylic acid, ethanol and carbethopendecinium can irritate an eroded inflamed canal. Do not add another cleaner or drop unless compatibility, spacing and tympanic safety are established; avoid traumatic cleaning.
  • Direct feline Otibiovin outcome evidence was not identified. Use feline-friendly restraint and analgesia, demonstrate dosing and reassess early; repeated forced treatment can make the high-frequency course impractical and unsafe.
  • Shake to redisperse permitted slight sediment, avoid dropper contact/cross-ear contamination, label first opening, store below 25 °C protected from light and discard after 12 days. Wear gloves, wash hands and avoid eye/skin/mucosal contact or ingestion.
Assessment sources
  1. Otibiovin Czech SPC2011
  2. Otibiovin exact2026
  3. MSD otitis externa2026
  4. Topical otic review2016
  5. Otitis susceptibility2006
  6. Feline otitis review2013
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Triamcinolone0.5 mg/ml Salicylic acid5 mg/ml Gentamicin2 mg/ml Carbethopendecinium bromide0.125 mg/ml
Formulation Type
Ear drops
Administration route
Into the ear
Manufacturer
Bioveta a.s. · Czechia
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ოტიბიოვინი
Verified on: 22 Oct 2026
 EU Yes, veterinary
№ 96/131/96-C
Verified on: 22 Oct 2026
 UK No
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026
Information not fully verified Dogs/cats: after otoscopy, cytology, cleaning and intact-tympanum confirmation, instil 4–5 drops 3–4 times daily initially, then 2–3 times daily after three days; usually 5–7 days, maximum 12. Use only for a diagnosed susceptible serious infection under the exact label restriction. Treat the primary cause and recheck clinically/cytologically.

OTOPET THERAPY, Ear drops

rifaximin 10 mg/ml + colistin sulfate 200000 IU/ml + miconazole 17.4 mg/ml + carbaryl 10 mg/ml + triamcinolone 0.908 mg/ml, ear drops for dogs and cats
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Complete authorised canine scope: external otitis associated with susceptible bacteria, fungi/yeasts, ear mites or inflammation
6.1/10
Situational / acceptable
vetman assessment

OTOPET THERAPY

rifaximin 10 mg/ml + colistin sulfate 200000 IU/ml + miconazole 17.4 mg/ml + carbaryl 10 mg/ml + triamcinolone 0.908 mg/ml, ear drops for dogs and cats
Assessed clinical scopeDog · Complete authorised canine scope: external otitis associated with susceptible bacteria, fungi/yeasts, ear mites or inflammation · Into the ear
Care settingVeterinary otoscopy/cytology-led treatment with careful cleaning, intact-tympanum confirmation, owner twice-daily application and clinical/cytologic recheck
vetman score 6.1/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, veterinary · № 1-03/44 · Verified on 23 Oct 2026

A situational five-active canine otic option when otoscopy and cytology genuinely support its relevant antibacterial, antifungal, acaricidal and steroid components. It should not be a default for every inflamed ear; no direct modern exact-product outcome programme was found, and tympanic, carbaryl, steroid and stewardship risks require controls.

Regulatory and scientific credibility8.5/10

Exact rifaximin 10 mg/ml, colistin sulfate 200,000 IU/ml, miconazole 17.4 mg/ml, carbaryl 10 mg/ml and triamcinolone 0.908 mg/ml identity, dog/cat route, regimen and perforation/handler restrictions are transparent in current Georgian and multiple current EU regulator records. Credibility is reduced by legacy development, no public modern exact-product assessment or quantified adverse-event/outcome dossier, and a broad inflammation-only label scope that conflicts with current stewardship.

Clinical efficacy6.0/10

Antibacterial, antifungal, acaricidal and anti-inflammatory components are mechanistically plausible for mixed canine otitis, and topical combination therapy is established when cytology supports it. No controlled exact-product outcome study was found, each component is not needed in every ear, and inflammation-only, resistant-rod, primary allergic or middle-ear disease is not solved by blanket five-active exposure.

Safety and tolerability4.5/10

The label reports no adverse reactions and permits reproduction, but modern quantified exact safety evidence is absent. Perforation is contraindicated; colistin/polymyxin-class ototoxicity concern, carbaryl cholinesterase inhibition/dermal absorption, topical steroid effects, contact irritation and dual-antibiotic selection pressure require active controls.

Clinical practicality5.0/10

A fixed 1-2 ml per ear avoids weight calculation and massage aids distribution. Twice-daily shaking, careful cleaning, relatively large oily volume for 7-10 days, restraint/handling, gloves, tympanum examination, cytology and recheck are substantial burdens; canal size makes the twofold volume range a clinician decision rather than a simple owner rule.

Full-course cost-effectiveness-

Current Georgian course price was unavailable; price is excluded from the denominator.

Important safety and use flags

  • Scope boundary: this canine score covers the full labelled external-otitis scope. It does not cover otitis media/interna, every inflamed ear, undiagnosed neurologic signs or use in another species.
  • Examine before treating: perform otoscopy, confirm an intact tympanic membrane and obtain cytology in every case (stained dry mount plus mite wet mount as appropriate). Culture/susceptibility is important with rods, chronic/recurrent disease, prior antimicrobial exposure or poor response.
  • Cause-directed care: identify allergy, foreign body, conformation, keratinisation/endocrine disease, polyp/mass, parasites or middle-ear disease. Antimicrobials treat secondary overgrowth/infection but do not correct the primary driver of recurrence.
  • Exact administration: shake well, clean carefully, instil 1-2 ml into each affected external canal and massage twice daily for 7-10 days. This is a clinician-selected fixed per-ear range, not a body-weight calculator; do not place it in an unexamined/perforated ear.
  • Stewardship: do not expose a cytology-negative merely inflamed ear to rifaximin, colistin and miconazole by default. At recheck, narrow/stop/switch according to clinical and cytologic response; persistent rods require culture and a documented plan rather than repeated empirical courses.
  • Parasitic boundary: repeat the course after 10 days only for confirmed/suspected parasitic otitis under the label plan. Confirm Otodectes, examine/treat relevant in-contact animals and manage the environment; this repeat instruction is not for every bacterial or yeast episode.
  • Tympanic/neurologic safety: stop and urgently reassess hearing loss, head tilt, nystagmus, ataxia, facial/Horner signs, severe pain or neurologic deterioration. Perforation is contraindicated and suspected middle-ear disease needs sampling/imaging/appropriate non-ototoxic care.
  • Carbaryl safety: wear impermeable gloves and avoid skin/eye contact. Review organophosphates and other cholinesterase inhibitors; hypersalivation, vomiting/diarrhoea, miosis, fasciculation, weakness, dyspnoea or seizure may indicate systemic cholinergic toxicity.
  • Dog safety/recheck: stop for marked irritation, worsening erythema/exudate, systemic steroid effects or hypersensitivity. Recheck clinical signs and cytology; visible improvement alone does not prove microbial resolution or control of allergic disease.
  • Reproduction and handling boundary: the exact label permits pregnancy and lactation at the recommended regimen, but modern quantified exact-product safety data are limited. Prevent licking/eye exposure, wash hands after use, keep the bottle from children and dispose as veterinary waste.
Assessment sources
  1. OTOPET GE register2026
  2. EU SPC 20232023
  3. OTOPET Latvia UPD2026
  4. OTOPET Slovak SPC2026
  5. AAHA otitis 20232023
  6. Merck otitis externa2026
  7. Feline chronic otitis review2021
  8. ESCCAP ear mites2016
  9. Merck carbamate safety2024
  10. FDA otic evidence control2015
Assessed: 23 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Complete authorised feline scope: external otitis associated with susceptible bacteria, fungi/yeasts, ear mites or inflammation
5.7/10
Weak evidence support
vetman assessment

OTOPET THERAPY

rifaximin 10 mg/ml + colistin sulfate 200000 IU/ml + miconazole 17.4 mg/ml + carbaryl 10 mg/ml + triamcinolone 0.908 mg/ml, ear drops for dogs and cats
Assessed clinical scopeCat · Complete authorised feline scope: external otitis associated with susceptible bacteria, fungi/yeasts, ear mites or inflammation · Into the ear
Care settingVeterinary otoscopy/cytology-led treatment with careful cleaning, intact-tympanum confirmation, owner twice-daily application and clinical/cytologic recheck
vetman score 5.7/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, veterinary · № 1-03/44 · Verified on 23 Oct 2026

A weak, highly selective feline otic option when mites and/or matching secondary microbes are documented and the tympanic membrane is intact. The absence of direct feline exact-product outcomes, broad inflammation-only label, contact-reaction concern and complex five-active safety/stewardship burden keep the score low.

Regulatory and scientific credibility8.5/10

Exact rifaximin 10 mg/ml, colistin sulfate 200,000 IU/ml, miconazole 17.4 mg/ml, carbaryl 10 mg/ml and triamcinolone 0.908 mg/ml identity, dog/cat route, regimen and perforation/handler restrictions are transparent in current Georgian and multiple current EU regulator records. Credibility is reduced by legacy development, no public modern exact-product assessment or quantified adverse-event/outcome dossier, and a broad inflammation-only label scope that conflicts with current stewardship.

Clinical efficacy5.0/10

The component roles are plausible, especially for confirmed Otodectes with secondary microbial inflammation, but no controlled exact-product feline outcome study was found. Feline otitis more often requires targeted investigation for mites, polyps, masses or middle-ear disease, and a broad five-active mixture for cytology-negative inflammation has a particularly weak evidence basis.

Safety and tolerability4.0/10

The label reports no adverse reactions and permits reproduction, but modern quantified feline safety evidence is absent. Cats may be particularly prone to otic contact reactions; perforation/ototoxicity, carbaryl systemic cholinergic exposure, topical steroid effects and unnecessary dual-antibiotic exposure make the safety ceiling lower than in dogs.

Clinical practicality5.0/10

A fixed 1-2 ml per ear avoids weight calculation and massage aids distribution. Twice-daily shaking, careful cleaning, relatively large oily volume for 7-10 days, restraint/handling, gloves, tympanum examination, cytology and recheck are substantial burdens; canal size makes the twofold volume range a clinician decision rather than a simple owner rule.

Full-course cost-effectiveness-

Current Georgian course price was unavailable; price is excluded from the denominator.

Important safety and use flags

  • Scope boundary: this feline score covers the full labelled external-otitis scope. It does not cover otitis media/interna, every inflamed ear, undiagnosed neurologic signs or use in another species.
  • Examine before treating: perform otoscopy, confirm an intact tympanic membrane and obtain cytology in every case (stained dry mount plus mite wet mount as appropriate). Culture/susceptibility is important with rods, chronic/recurrent disease, prior antimicrobial exposure or poor response.
  • Cause-directed care: identify allergy, foreign body, conformation, keratinisation/endocrine disease, polyp/mass, parasites or middle-ear disease. Antimicrobials treat secondary overgrowth/infection but do not correct the primary driver of recurrence.
  • Exact administration: shake well, clean carefully, instil 1-2 ml into each affected external canal and massage twice daily for 7-10 days. This is a clinician-selected fixed per-ear range, not a body-weight calculator; do not place it in an unexamined/perforated ear.
  • Stewardship: do not expose a cytology-negative merely inflamed ear to rifaximin, colistin and miconazole by default. At recheck, narrow/stop/switch according to clinical and cytologic response; persistent rods require culture and a documented plan rather than repeated empirical courses.
  • Parasitic boundary: repeat the course after 10 days only for confirmed/suspected parasitic otitis under the label plan. Confirm Otodectes, examine/treat relevant in-contact animals and manage the environment; this repeat instruction is not for every bacterial or yeast episode.
  • Tympanic/neurologic safety: stop and urgently reassess hearing loss, head tilt, nystagmus, ataxia, facial/Horner signs, severe pain or neurologic deterioration. Perforation is contraindicated and suspected middle-ear disease needs sampling/imaging/appropriate non-ototoxic care.
  • Carbaryl safety: wear impermeable gloves and avoid skin/eye contact. Review organophosphates and other cholinesterase inhibitors; hypersalivation, vomiting/diarrhoea, miosis, fasciculation, weakness, dyspnoea or seizure may indicate systemic cholinergic toxicity.
  • Feline contact-reaction warning: cats may deteriorate from topical contact dermatitis. Stop if erythema, suppuration, pruritus or pain worsens despite improving cytology; investigate polyp/mass and middle-ear disease rather than layering additional products.
  • Reproduction and handling boundary: the exact label permits pregnancy and lactation at the recommended regimen, but modern quantified exact-product safety data are limited. Prevent licking/eye exposure, wash hands after use, keep the bottle from children and dispose as veterinary waste.
Assessment sources
  1. OTOPET GE register2026
  2. EU SPC 20232023
  3. OTOPET Latvia UPD2026
  4. OTOPET Slovak SPC2026
  5. AAHA otitis 20232023
  6. Merck otitis externa2026
  7. Feline chronic otitis review2021
  8. ESCCAP ear mites2016
  9. Merck carbamate safety2024
  10. FDA otic evidence control2015
Assessed: 23 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Rifaximin10 mg/ml Colistin200000 IU/ml Miconazole17.4 mg/ml Carbaryl10 mg/ml Triamcinolone0.908 mg/ml
Formulation Type
Ear drops
Administration route
Into the ear
Manufacturer
Fatro S.p.A. · Italy
Manufacturer (register)
FATRO S.p.A. Ltd, Italy
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 36, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ოტოპეტ თერაპი
№ 1-03/44
Verified on: 23 Oct 2026
 EU Yes, veterinary
№ V/NRP/02/1490; 96/019/00-C; 96/151/99-S
Verified on: 23 Oct 2026
 UK No
Verified on: 23 Oct 2026
 US No
Verified on: 23 Oct 2026
Controlled in Georgia
Unknown
Information not fully verified Complete labelled scope: dog/cat otitis externa associated with susceptible bacteria, fungi/yeasts, ear mites or inflammation. Shake, clean carefully, instil 1-2 ml per affected external canal and massage twice daily for 7-10 days; repeat after 10 days only for parasitic otitis. This is a fixed per-ear volume, not a body-weight dose. Cytology and otoscopy determine whether the five-active combination is appropriate; recheck to documented resolution.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗